Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (4326)	4/30/2003 11:34:32 AM
From: StockDung	Read Replies (1) \| Respond to of 5582

Kevin, didnt you hear Dan. He said that the Mayo clinic should contact GUMM for a possible license agreement. lol You know the Mayo clinic would come to GUMM rather that billion dollar corporations because er er i dont know. From: Dan Zimmermann Wednesday, Apr 30, 2003 11:26 AM Respond to of 4328 "It's over" is kind of strong and hypish, and very far from the truth, "Truthseeker". I kind of doubt that there's any connection between the drop in MTXX and Mayo's patent for a sinusitis remedy. They don't even have anyone to produce the product yet. Maybe they should contact Matrixx about a licensing deal. Even if they do put a product on the market in two or three years, do you really think it would materially affect this company's sales? What a joke.

To: Kevin Podsiadlik who wrote (4326)	4/30/2003 11:34:35 AM
From: DanZ	Read Replies (1) \| Respond to of 5582

You're playing games with the semantics. We are saying the same thing. Have fun arguing with yourself on that point. <MTXX forecasted 30% revenue growth, that's all.> Last night's press release only talked about 30% revenue growth. The company provided guidance related to the rest of the projections in my post at the last conference call. I guess you didn't listen to it. They said exactly what I said about R&D, advertising, and operating expenses. Ignorance is bliss, isn't it?